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Abstract: Anakinra is an interleukin (IL) receptor antagonist that works by blocking the
biological activity of IL-1 by competitively inhibiting binding of IL-1 to the type 1 interleukin
receptor. IL-1 production is induced in response to inflammatory stimuli and mediates various
physiological mechanisms, including inflammation and immunological reactions. Patients with
neonatal onset multisystem inflammatory disease (NOMID) produce excess IL-1β, a major
proinflammatory cytokine that regulates innate immune responses. Anakinra binds competitively
and this results in a rapid reduction in disease severity. NOMID, also known as chronic infantile
neurologic, cutaneous, articular syndrome, is the most severe clinical phenotype in the spectrum of cryopyrin-associated periodic syndromes. It is characterized by cutaneous symptoms,
arthropathy, and central nervous system involvement. Extensive studies in patients with NOMID
have led to advances in characterizing the extent of organ-specific involvement and damage that
occurs with chronic overproduction of IL-1β. NOMID is caused predominantly by mutations
in the NLRP3/CIAS1 gene that encodes for the protein cryopyrin, leading to activation of the
“NLRP3 inflammasome complex”. This in turn regulates the maturation and secretion of the
inflammatory cytokine, IL-1β. The clinical value of IL-1β has been demonstrated by the positive
response of patients after treatment with anakinra, with rapid improvement in clinical symptoms,
markers of inflammation, and a significant decrease in major organ manifestations.
Keywords: neonatal onset multisystem inflammatory disease, chronic infantile neurologic,
cutaneous, arthritis syndrome, NLRP3, CIAS1, interleukin-1β
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Neonatal onset multisystem inflammatory disease (NOMID) is a monogenic autoinflammatory syndrome and constitutes one of the three known cryopyrin-associated periodic syndromes (CAPS). These syndromes occur as a result of an autosomal dominant
or de novo mutation of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene
on chromosome 1q44.1 The three clinical entities that belong to the group of diseases
known as CAPS were discovered at different times, and initially described separately as
distinct diseases. It was not until a common genetic defect was identified that these
three diseases were recognized as separate clinical phenotypes of the same disease
mechanism. The three forms of CAPS are familial cold autoinflammatory syndrome
(FCAS), Muckle–Wells syndrome (MWS), and NOMID, or as it is known in Europe,
chronic infantile neurological, cutaneous, articular (CINCA) syndrome. The discovery
of a common etiology for these diseases is an important step in the understanding
of autoinflammatory disease. The clinical spectrum, including both similarities and
differences in presentation of the three diseases, adds to the intrigue surrounding the
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common genetic defect. Why does a single common defect
lead to such diverse clinical symptoms and signs?
Along the clinical spectrum of CAPS, all three diseases
present in the neonatal period, although there have been
reports of presentation after infancy and even into adulthood.
Common features of these diseases include inflammation
of the skin, eyes, bones, joints, and meninges. In addition,
severe fatigue, fever, myalgia, chronic anemia, and learning disabilities are some of the other symptoms which are
commonly seen.2 The similarities and differences of these
diseases are shown in Table 1. These diseases make up a
group of rare hereditary autoinflammatory diseases, with
an estimated population frequency in the range of 1–3 per
million.3
The discovery of a genetic basis for these disorders has
significantly impacted new approaches to treatment. The
CIAS1 gene, which is mutated in CAPS patients, has been
discovered to be involved in inflammation and apoptosis.4
In response to inflammation, interleukin (IL)-1β is secreted
and is known to mediate the peripheral immune response
during infection and inflammation. It has been reported
that patients with NOMID and other CAPS disorders have
higher IL-1β levels compared with their healthy counterparts. Thus, the mutation in CAPS is a gain-of-function
mutation.
As a result of the pathogenesis, targeting the IL-1β pathway has proven to be a successful approach in the treatment
of patients with CAPS, specifically NOMID. Recent advances
in the development of drugs targeting IL-1β have led to the
introduction of several anti-IL-1β drugs, including anakinra,
rilonacept, and canakinumab.

Cryopyrin-associated periodic
syndromes
The three cryopyrin-associated periodic syndromes are
FCAS, MWS, and NOMID. Chronic inflammation, with
recurrent fever, cutaneous rash, and joint symptoms, are common characteristics of these diseases. As they progress from
the mildest form to the most severe form, the rash becomes
less prominent, and other more severe features dominate
the clinical presentation.5 This spectrum of disease severity
is shown in Table 1.

Familial cold autoinflammatory syndrome
FCAS is the mildest phenotype of the autoinflammatory
diseases and is characterized by urticarial rash, low grade
fever, polyarthralgias, and conjunctivitis induced by exposure
to cold, occurring primarily in infancy.6 These episodes are
generally self-limiting and resolve within 24 hours. Other
symptoms induced by cold exposure include profuse sweating,
drowsiness, headache, extreme thirst, and nausea.7 Although
these symptoms have a significant impact on quality of life,
they are not associated with organ damage or disability.
Laboratory studies show elevated neutrophil counts, erythrocyte sedimentation rate, and C-reactive protein.

Muckle–Wells syndrome
MWS is the intermediate phenotype and is characterized by
recurrent episodes of rash and fever that may develop in the
first few years of life. The rash can be cold-induced, urticarial, or erythematous. Musculoskeletal symptoms include
arthralgia, arthritis, and myalgias. These features occur
episodically and can last anywhere from one day to 2 weeks.

Table 1 Similarities and differences between CAPS with symptom progression from the mildest form to the most severe form of the
disease
FCAS

MWS

NOMID/CINCA

Severity
Triggers
Fever/rash
Joint involvement
Neurological involvement

Low
Cold-induced
Usually daily symptoms
Arthralgia
None

Medium
None
Variable symptoms (rare to daily)
Arthralgia/arthritis
None

Eye involvement
Hearing loss
Amyloidosis
Inheritance

Conjunctivitis
None
No
Autosomal dominant

Pathophysiology

Mutation in CIAS1 gene
encoding for cryopyrin
Anti-IL-1 therapy

Conjunctivitis, uveitis
Frequent (60%)
Frequent (25%)
Autosomal dominant or
de novo (rare)
Mutation in CIAS1 gene encoding
for cryopyrin
Anti-IL-1 therapy

High
None
Variable symptoms (rare fever, daily rash)
Arthralgia, arthritis, overgrowth arthropathy
Chronic aseptic meningitis (headache,
mental retardation)
Uveitis, papillary edema, optic neuritis
Frequent (.60%)
Frequent (25%)
De novo (typical) or autosomal dominant
(rare)
Mutation in CIAS1 gene encoding for
cryopyrin
Anti-IL-1 therapy

Treatment

Abbreviations: IL, interleukin; FCAS, familial cold autoinflammatory syndrome; MWS, Muckle–Wells syndrome; NOMID, neonatal onset multisystem inflammatory disease;
CINCA, chronic infantile, neurological, cutaneous, articular syndrome; CAPS, cryopyrin-associated periodic syndromes.
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Sequelae of MWS may include sensorineural hearing loss and
secondary renal amyloidosis with nephropathy (a complication of late stage disease).8 The hearing loss is progressive,
likely leading to deafness by adolescence, and the amyloidosis may progress to impaired renal function. Laboratory
findings include generalized leukocytosis and elevations in
acute-phase reactants.

Neonatal onset multisystem
inflammatory disease
NOMID is the most severe phenotype, with the course of
disease being more chronic than recurrent. It manifests in the
first few weeks of life with an urticarial-like rash, arthropathy,
and central nervous system involvement.9 The rash is typically
nonpruritic and can vary with disease activity. Fever is usually mild in this disease. Individuals have atypical “facies”,
including frontal bossing, a saddle-back nose, and mid-face
hypoplasia. The disease also causes bony overgrowths predominantly involving the knees and the distal extremities of
the hands and feet. Chronic inflammatory polyarthritis may
also be present, resulting in bone erosions. The severity of
bone and joint involvement is variable, with approximately
two thirds of patients developing arthralgia and transient
swelling during flares, and the remaining one third developing
severe and disabling arthropathy, resulting in gross deformity
of the patella and epiphyses of the long bones.10
The radiographic findings in severe cases are characterized
by a “bread crumb” appearance of the patella and epiphyses.
Central nervous system manifestations can be the most devastating, and include chronic septic meningitis, increased
intracranial pressure, cerebral atrophy, ventriculomegaly,
sensorineural hearing loss, and chronic papilledema with
associated optic nerve atrophy and loss of vision. Mental
retardation and seizures are also present.9
Findings suggestive of an ongoing inflammatory process
include lymphadenopathy, splenomegaly, elevations in
acute-phase reactants (erythrocyte sedimentation rate and
C-reactive protein), leukocytosis, cerebrospinal fluid neutrophilia, hyperglobulinemia, and chronic anemia. Failure
to control the inflammation can lead to irreversible organ
damage and disability. Therefore, it is imperative to start
treatment as soon as the disease is suspected.

Pathophysiology
of autoinflammatory syndromes
Genetics of cryopyrin
The discovery of a genetic basis for NOMID has led to its
placement among the other cryopyrinopathies, all of which
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are caused by mutations in the CIAS1 gene. The genetic
defect was first defined in FCAS in 2000, and subsequently
the same gene was found to be responsible for MWS.7,11 The
genetic defect was identified in NOMID in 2002. There are
many mutations that lead to CAPS, and are located in exon 3
of the CIAS1 gene. All are gain-of-function mutations and
are essential to the activation of intracellular caspase-1 and
processing of IL-1β.12

Mechanism of action of cryopyrin
CIAS1 encodes the cryopyrin molecule, which combines with
a group of interacting proteins to form a macromolecular complex called the “inflammasome,” that is important in the innate
immune response due to its role as a molecular platform.13
There are at least four inflammasomes, designated NLRP1,
NLRP3, NLRC4, and AIM2.14 The NLRP3 inflammasome,
which is directly responsible for CAPS, contains three separate
components that are all involved in the activation of proinflammatory cytokines, such as IL-1β and IL-18. These components
include NLRP3/cryopyrin, an apoptosis-associated speck-like
protein (ASC) containing a CARD (caspase activation and
recruitment domain) and a leucine-rich repeat domain.
The signals leading to inflammasome activation and generation of proinflammatory cytokines such as IL-1β include
danger-associated molecular patterns and pathogen-associated
molecular patterns. There have been many danger-associated
molecular patterns described, including cholesterol or uric acid,
toxins, adenosine triphosphate (ATP), and ultraviolet B radiation.15–17 Pathogen-associated molecular patterns that have been
shown to activate NALP3 include bacteria such as Neisseria
gonorrhea and viruses such as Influenza A.18,19 Once NLRP3 is
stimulated, it oligomerizes and binds the adaptor protein ASC.
ASC interacts with cryopyrin, leading to activation of nuclear
factor kappa B and caspase-1, and apoptosis.20
Activation of caspase-1 results in cleavage of pro-IL-1β
and pro-IL-18 into their mature forms (IL-1β and IL-18,
respectively) which are secreted by the cell.21 Thus, activated
cryopyrin induces release of the active form of IL-1β. This
process is illustrated in Figure 1. In all three phenotypes
of CAPS, the gain-of-function mutation of the NLRP3
gene forms a defect in this pathway, resulting in increased
inflammasome activation, which enhances and accelerates
production of IL-1β, leading to the inflammatory symptoms
seen in NOMID.22

Therapeutic targets and strategies
The disorders caused by CIAS1 mutations are not distinct
diseases, but represent a clinical continuum of phenotypes.

submit your manuscript | www.dovepress.com

Dovepress

17

Dovepress

Bachove and Chang

DAMPs
External ATP
Uric acid
Cholesterol
Toxins
UVB radiation

PAMPs
Neisseria gonorrhea
Influenza A

NLRP3 or
cryopyrin
(CIAS1)

LRR

The NLRP3 inflammasome

ASC
(PYCARD)
Pro
IL-1β
Pro-caspase

Caspase and
NFκB

IL-1β
IL-18

Anakinra
CAPS
Figure 1 Pathophysiology of CAPS. Activation of the NLRP3 inflammasome is triggered by exposure of immune cells to a variety of danger-associated molecular patterns
and pathogen-associated molecular patterns. The leucine-rich repeat domain of the NLRP3 is thought to serve as an autoinhibitor by self-folding. The molecule spreads out,
dimerizes, and associates through homotypic interaction with the ASC adaptor protein to mediate the proteolytic processing of pro-caspase 1 to caspase-1. The ASC protein
also interacts with cryopyrin. When cryopyrin binds to ASC it can result in NFκB and caspase-1 activation. Once caspase-1 is activated, it results in cleavage of pro-IL-1β and
pro-IL-18 into their mature forms IL-1β and IL-18, respectively, which is secreted by the immune cell. Thus, activated cryopyrin induces release of the active form, IL-1β.
Abbreviations: DAMPs, danger-associated molecular patterns; PAMPs, pathogen-associated molecular patterns; IL, interleukin; ASC, apoptosis-associated speck-like
protein; CAPS, cryopyrin-associated periodic syndromes; UVB, ultraviolet B; LRR, leucine-rich repeat; ATP, adenosine triphosphate.

It was discovered that the same nucleotide substitution in
CIAS1 may be associated with a different clinical subtype in
different patients.23 It is also interesting that various mutations
in CIAS1 result in different levels of caspase-1 activation,
thereby leading to such extreme clinical spectrum ranges
as seen in the different phenotypes of CAPS.24 In addition,
CIAS1 mutations may not always be the culprit in diseases
involving cryopyrin. This has been evident in several patients
with FCAS, MWS, and NOMID who do not have mutations
in CIAS1, but have the classic disease phenotype.
Most CIAS1 mutations are inherited in an autosomal
dominant pattern, although de novo cases have been reported.
Mutations in CIAS1 were found in 50% of NOMID patients
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and mutations occurred de novo in five of seven patients with
NOMID syndrome.25 This suggests that the severity and presence of the disease is likely to be influenced by other genetic
and environmental factors.26
The CIAS1 mutation in CAPS is a gain-of-function
mutation in cryopyrin, leading to activation of proinflammatory cytokines. IL-1, one of the proinflammatory cytokines
activated in CAPS, is the primary target for drugs such as
anakinra. It was originally thought that anakinra should be
used in the treatment of NOMID patients with CIAS1 mutations only. However, a number of studies have demonstrated
that anakinra is effective for treatment of the disease regardless of the gene defect present. For example, recent work by
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Lovell et al demonstrated improvement of NOMID symptoms
in a patient with a normal CIAS1 gene sequence after treatment with anakinra.27 In another study by Hawkins et al, three
patients were diagnosed with NOMID on clinical grounds and
later revealed no CIAS1 mutations. After receiving anakinra,
all three patients had resolution of fever, rash, joint inflammation, and headache, with normalization of C-reactive protein
and erythrocyte sedimentation rate.28 These findings suggest
that regardless of the upstream mechanism, such as CIAS1
defects, correction of the downstream effect including IL-1β
overproduction ameliorates symptoms of the disease.
Another observation has been the presence of somatic
mosaicism in patients with CIAS1-related disease. Tanaka
et al were able to identify that NOMID/CINCA resulted
from the mutant NLRP3 gene in these cases of somatic
mosaicism, in which mutant cells accounted for 4.2%–35.8%
of all blood cells.29

Treatment
Traditional treatment
Traditional treatment of CAPS has utilized anti-inflammatory
agents such as glucocorticoids, nonsteroidal anti-inflammatory
agents, antihistamines, and other i mmunosuppressive

1993 – anakinra manufactured by the
pharmaceutical company Amgen, Inc.

2001 – anakinra approved by the US FDA
for rheumatoid arthritis in patients
18 years of age and older who have
failed one or more DMARDs

2004–2006 – anakinra used in FMF
and HIDS

medications, all without significant success. While there
have been modest improvements with high-dose oral corticosteroids and thalidomide, these agents have not been
well tolerated due to their side effect profile. Because of the
discovery that IL-1β is a potent proinflammatory cytokine
which is upregulated by mutations in CIAS1, three new therapies have been identified which use different approaches to
achieve the same goal.

Anakinra: an IL-1 receptor antagonist
Exploration of IL-1 receptors started in 1993 with the
introduction of anakinra, a recombinant, nonglycosylated
version of IL-1 receptor antagonist (IL-1RA) prepared
from cultures of genetically modified Escherichia coli using
recombinant DNA technology. It consists of 153 amino
acids and differs from native human IL-1RA in that it has
the addition of a single methionine residue on its amino
terminus. Since 1993, anakinra has been well studied and
has been shown to control many diseases, including CAPS.
Use of anakinra in different diseases is shown in a timeline in Figure 2. Anakinra currently dominates the field of
IL-1 therapeutics, mostly because of its excellent safety
profile and tolerability by pediatric and adult patients.

1993 – anakinra first used in
rheumatoid arthritis

2003 – anakinra used in MWS

2005 – anakinra used in adult onset
Still’s disease and systemic juvenile
idiopathic arthritis

2007 – anakinra tested in type 2
diabetes

2010 – anakinra used in STEMI and
CAPS
2012 – anakinra used in heart failure
2013 – approved by the US FDA for the
treatment of NOMID patients
Figure 2 Timeline highlighting use of anakinra in various disease states.
Abbreviations: CAPS, cryopyrin-associated periodic syndromes; DMARDs, disease-modifying antirheumatic drugs; US FDA, US Food and Drug Administration; FMF,
familial Mediterranean fever; HIDS, hyper-IgD syndrome; STEMI, ST elevation myocardial infarction; NOMID, neonatal onset multisystem inflammatory disease; MWS,
Muckle–Wells syndrome.
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Anakinra was approved by the US Food and Drug Administration in January 2013 for the treatment of NOMID, and its
use is expected to increase, given that it may have a beneficial
effect in other disease states.
A role for anakinra in the treatment of CAPS has been
evident in prevention of clinical symptoms and acute-phase
elevations in patients with FCAS,30 an ability to induce
complete remission in MWS, and resolution of symptoms
including uveitis, rash, and fever in NOMID patients.31,32
The possibility of reducing the clinical symptoms of
inflammation and improvement in quality of life makes
this discovery extremely important. The safety and efficacy
of anakinra have been tested in a number of studies, with
promising results.
The short-term efficacy and rapid response to anakinra
was first reported in a study by Hawkins et al, who followed
three severely ill family members carrying NALP3/CIAS1
mutations. It was reported that clinical features such as rash,
fever, conjunctivitis, and arthralgia improved within 4 hours
after the first injection, and serologic remission was achieved
within one week. The study also reported a rapid decrease
in C-reactive protein levels and a resolution of hematologic
abnormalities in all patients.33
Immediate resolution of clinical symptoms was also
evident in a retrospective study by Leslie et al, who demonstrated complete remission of rash, fever, conjunctivitis, and
rheumatic aches within 4–12 hours of starting anakinra in 15
patients treated for 39 months. These patients were treated
starting with daily 100 mg subcutaneous injections and then
reduced to 20–50 mg to determine efficacy at lower doses.
All patients improved on the lower doses, except for two
children who continued to receive 100 mg daily injections.
Monthly measurements of C-reactive protein and serum
amyloid A levels were reviewed, and demonstrated normalization within one week in all patients. In addition, nephrotic
syndrome remitted within 8–33 months in three patients with
AA amyloidosis.34
In a prospective study, Goldbach-Mansky et al demonstrated improvement in symptoms such as urticarial-like rash
and acute-phase reactants, in addition to improvements in
hearing and neurosensory deficits in 18 children with CINCA/
NOMID (12 with identifiable CIAS1 mutations) followed for 6
months. The treatment was able to effectively control most of
the clinical manifestations, including chronic meningitis and
papilledema. Abnormal cochlear enhancement was detected in
17 patients on magnetic resonance imaging, and although 13
of these patients had improvement of cochlear enhancement,
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one had a regression and three had no improvement after
3 months of therapy. Primary outcomes were decreases in
C-reactive protein, erythrocyte sedimentation rate, and serum
amyloid A levels, as well as daily improvement in ratings of
symptoms at 3 months, all of which also remained low at 6
months. In total, eight of 18 patients showed remission of
inflammatory symptoms after 3 months and the remaining ten
patients after 6 months. Furthermore, treatment with anakinra
reduced secretion of IL-1β from cultured peripheral blood
mononuclear cells after 6 months of therapy.32
Not only has anakinra been useful in NOMID patients, but
it has also shown improvement in patients with other CAPS
disorders. In a study by Kuemmerle-Deschner et al, anakinra
proved to be an effective and safe therapy in 12 children and
adults with severe MWS over a median of 11 (5–14) months.
There was rapid resolution of constitutional symptoms,
severe disease-associated fatigue, and musculoskeletal,
skin, and eye symptoms after 2 weeks of therapy. Classical
markers of inflammation improved in the majority of these
patients. The erythrocyte sedimentation rate normalized in
all but one patient (92%), and the C-reactive protein value
normalized in 45% of those who had an elevation at baseline.
While improvement in erythrocyte sedimentation rate was
detectable as early as 2 weeks and then plateaued, C-reactive
protein levels continued to improve further until the last
follow-up visit.35
Similar observations were reported in a study by Hoffman
et al, in which anakinra was able to prevent cold-associated
acute inflammation in four patients with FCAS subjected to
cold challenge. When subjected to cold challenge without
anakinra treatment, the patients with FCAS developed low
grade fever, rash, and arthralgia starting 1–2 hours after cold
challenge. The patients with FCAS treated with anakinra
before cold challenge did not develop any of the signs or
symptoms that they had developed during the previous cold
challenge. These patients did develop a mild rash after the
initial dose, but had no symptoms after the second dose and
remained symptom-free for 24–48 hours.30
Given that use of IL-1RA is relatively new, its efficacy
and safety on a long-term basis is not well documented.
Several studies have assessed the long-term effects of IL-1
antagonists in different phenotypes of CAPS patients, including NOMID/CINCA. Lepore et al demonstrated the longterm effects and sustainability of control of inflammatory
manifestations in ten CINCA patients who were followed
for 26–42 months. They demonstrated complete control of
the inflammatory manifestations, such as skin rash, arthritis/
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arthralgia, elevated acute-phase reactants, and inflammatory
anemia for up to almost 5 years of follow-up. Continuous
treatment with anakinra completely controlled some of the
neurologic manifestations such as chronic meningitis and
headache (although control of papilledema and amelioration
of hearing loss was not achieved).36 In a study by Neven et al,
the long-term effects of anakinra for up to 26–42 months
have also been demonstrated in treating a broad range of
systemic manifestations, neurologic involvement, and growth
parameters. The magnitude of these responses was dosedependent, with improvement in constitutional symptoms
such as fever, rash, and arthralgia at 1 mg/kg/day. Higher
doses (2–3 mg/kg/day) were necessary in five patients with
persistent headache and papilledema after one year of therapy
in order to achieve ongoing normalization of biologic inflammation marker levels and decreases in central nervous system
inflammation.10 However, central nervous system inflammation normalized in only one patient, with improvement and
stabilization in a total of four patients. These data indicate
that long-term remission is possible, but this is difficult to
achieve in severe cases of NOMID.
Leslie et al also demonstrated a positive outcome in
15 MWS patients followed for a median of 17 (1–39)
months. All patients showed a sustained response to drug
therapy without dosage adjustments to prevent recurrence of symptoms. There was significant improvement
in renal disease measured by scintigraphic scan for
amyloidosis.34
Based on the studies to date, it is clear that anakinra is
a major advance in the management of NOMID and other
CAPS phenotypes. To date, there have been very few side
effects demonstrated with administration of anakinra. Local
injection site reactions, including itching, swelling and
redness, have been reported to occur in 42% of patients.35
Similar rates of local site reactions were reported in the
other studies mentioned above.32–34 However, injection site
reactions are uncommon after the first month of therapy.
Despite the success of anakinra, the short half-life of
4–6 hours requires daily subcutaneous injections. Treatment
becomes a lifelong process, because drug withdrawal leads
to disease flares. As discussed below, other IL-1-blocking
agents with longer half-lives are also being developed and
tested with success.

Rilonacept: IL-1 trap
Rilonacept, an IL-1 trap cytokine inhibitor, has been used
effectively in the treatment of many diseases. Rilonacept utilizes
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cytokine trap technology, which allows for effective inhibition
due to multicomponent “traps” containing binding sites for the
cytokine as well as their accessory proteins. Cytokine traps have
been very effective in autoinflammatory diseases because they
bind to their respective cytokines with high affinity.37 Rilonacept
was first approved by the US Food and Drug Administration
in 2008 specifically for FCAS and MWS patients over the age
of 11 years. The drug has a half-life of 8.6 days, which makes
weekly injections an improvement over daily injections of anakinra. The safety and efficacy of weekly subcutaneous injections
(160 mg/week) of rilonacept have recently been evaluated in
patients with FCAS and MWS. The efficacy of treatment was
confirmed in a one-year study, with five FCAS patients having
confirmed mutations.38 All five patients showed improvement
of symptoms, with the maximum improvement at days 6–10.
All patients were given doses of 160 mg weekly, although
remission did not occur in four patients, who were then given
doses of 320 mg. All five patients tolerated the drug very well
with no injection site reactions, and showed long-term efficacy
at the 2-year follow-up.
In two sequential, double-blind, placebo-controlled trials of patients with FCAS or MWS, all patients had positive CIAS1 gene mutations. In the first study, a randomized
6-week trial, 47 patients received either rilonacept at a dose
of 160 mg/week or placebo. The patients receiving the drug
showed a decrease in disease activity score of 84% compared
with 13% in patients receiving placebo. In the second study,
patients were enrolled in a 9-week, single-blind treatment
period followed by a 9-week, double-blind withdrawal period.
Patients on rilonacept therapy during the “withdrawal” period
demonstrated improved efficacy compared with the group on
placebo.39 Patients treated with rilonacept had mild injection
site reactions.

Canakinumab: IL-1β monoclonal antibody
Canakinumab is a human IL-1β monoclonal antibody with
very good efficacy in the treatment of CAPS patients. It
has a long half-life of 26 days, which allows for a dosing
schedule of subcutaneous injections every 8 weeks. This
dosing schedule is favorable compared with that of anakinra
(daily) and rilonacept (weekly). Canakinumab was approved
by the US Food and Drug Administration in 2009 for use in
CAPS patients over 4 years of age. The first open-label clinical trial for canakinumab was completed in 2008 in seven
mutation-confirmed CAPS patients. In these patients, IL-1β
production fell to levels similar to those seen in unaffected
healthy controls after 8 weeks of therapy.40
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In another double-blind, randomized trial in 2008,
35 CAPS patients (all with confirmed NLRP3 mutations),
enrolled in a three-part, 48-week trial to receive 150 mg
of canakinumab every 8 weeks. In the first part, 34 of
the 35 patients had a complete response in as little as
8 days, which was confirmed by physician assessment of
disease activity and rash, as well as C-reactive protein and
serum amyloid A levels. In the second part of the study,
15 patients received the drug and 16 patients received
placebo. All 15 patients in the treatment group experienced remission of symptoms, while 13 of those in the
placebo group experienced disease flares and increased
C-reactive protein. In the third part, the 31 patients showed
sustained clinical remission with minimal disease activity,
disappearance of rash, and normalization of C-reactive
protein and serum amyloid A levels. Complete remission
was seen in 97% of the patients on treatment, and randomization to placebo led to disease flares in 81% of patients,
whereas all patients who received the drug remained
in remission. Injection site reactions occurred in up to
9% of patients, and up to 14% of the patients developed
vertigo.41

Side effects of biological
modulators of IL-1/IL-1R
The primary side effects of anakinra in NOMID have been
reported to be local injection site reactions, including redness, rash, itchiness, or pain. Other skin reactions such
as bruising or bleeding can occur, but are very rare. Skin
reactions usually resolve after 1–2 weeks. Biological modulators carry a risk of infection, and this has been reported
when anakinra is used to treat rheumatoid arthritis but not
NOMID. Other reactions may include headaches, vomiting,
arthralgias, pyrexia, and nasopharyngitis. The most common side effects of canakinumab in the treatment of CAPS
include nasopharyngitis, diarrhea, nausea, influenza, and
headache. A similar side effect profile was also described
with rilonacept, with injection site reactions being the most
common adverse effect.

Discussion
Remarkable advances have been made in our understanding of the molecular and genetic pathways responsible for
the clinical phenotypes of NOMID. Studying patients with
NOMID has allowed us to define the extent of disease damage caused by overproduction and secretion of IL-1β due to
mutations in the CIAS1 gene. The discovery of these gene
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mutations has led to major advances in the treatment of this
rare disease and led to rapid resolution of its inflammatory
manifestations. IL-1 blocking agents have been found to
be helpful not only in NOMID and other milder forms of
CAPS, but also in other IL-1-mediated diseases, such as
familial Mediterranean fever, gout/pseudogout, osteoarthritis, rheumatoid arthritis, type 2 diabetes mellitus,
pyoderma gangrenosum, and other diseases as noted in
Table 2. Numerous studies have shown positive effects of
anakinra in patients with the above disorders. Significant
studies are described in Table 3. Anakinra offers an ideal
treatment option for many of these diseases due to its
excellent safety profile and ease of administration subcutaneously or intravenously. The short half-life of 4–6
hours offers an additional safety benefit and allows for
short-term use.
Studies of patients with NOMID have been imperative
in characterizing the extent of organ-specific inflammatory
manifestations. The disease severity in NOMID is extreme
and requires close monitoring of the involved organs and
aggressive treatment to control both systemic and organspecific manifestations. It is important for patients with
NOMsID to receive an early diagnosis and prompt treatment,
because cumulative inflammation can lead to progressive and
permanent organ damage. Lepore et al36 reported on patients
who received an early diagnosis and prompt treatment, and
had not shown any new disease-related manifestations such

Table 2 Examples of conditions treated by anakinra
Inflammatory diseases
Gout and pseudogout
Type 2 diabetes
Pustular psoriasis
Sjögren’s syndrome
Joint, bone, and muscle diseases
Rheumatoid arthritis
Ankylosing spondylitis
 Erosive osteoarthritis of the hand
Osteomyelitis
Hereditary systemic autoinflammatory disease
Cryopyrin-associated periodic syndrome
Hyper-IgD syndrome
Familial Mediterranean fever
Periodic fever, aphthous stomatitis, pharyngitis, and adenitis
System inflammatory diseases
Systemic juvenile idiopathic arthritis
Adult onset Still’s disease
Schnitzler syndrome
Behçet’s disease
Synovitis, acne, pustulosis, hyperostosis, osteitis
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Juvenile idiopathic
arthritis

Type 2 diabetes

SAPHO syndrome

Hyper-IgD
syndrome/periodic
fever syndrome
Ankylosing
spondylitis

Lequerre
et al42

Larsen
et al43

Wendling
et al44

Rigante
et al45
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Adult onset Still’s
disease

Acute gouty
arthritis

Nordstrom
et al50

Ghosh
et al51

Retrospective chart
review

Open, randomized,
multicenter study

Case study

Case series

Case report

Open-label study

Case study

Case study

Placebo-controlled,
randomized,
controlled
Placebo-controlled,
double-blind

Study design

2013

2012

2012

2009

2008

2004

2006

2012

2007

2008

Year

26

22

4

3

1

9

1

6

70 (34 anakinra,
36 placebo)

20

Patients (n)

Unknown

8 weeks and
6 months

6–18 months

3 months

20 months

3 months

18 months

1 month

15 months
(range
2–27 months)
13 weeks

Mean
follow-up

100 mg daily

100 mg daily

100 mg daily

100 mg daily

100 mg daily

100 mg daily

1 mg/kg/day

100 mg daily

100 mg daily

1–2 mg/kg/day

Dose of
anakinra

Improvement in Bath AS
functional index, disease activity
index and quality of life,
improvement in inflammatory
markers, back pain. and MRI
(axial enthesitis and osteitis)
Remission in fever, improvement
in oral and genital ulcers, no
evidence of thrombophlebitis or
decrease in inflammatory markers
Improvement in pain, and global
handicap. NSAIDs were withdrawn
in all patients
Complete remission of attacks,
partial effect on constitutional
symptoms, normalization of CRP
levels
Normalization of CRP and ferritin
and reduction/discontinuation
of corticosteroids. Significant
improvements in physical health
Complete resolution of symptoms
(pain, swelling, erythema, warmth)

15 patients (93% response to
systemic symptoms), steroid
reduction in 45%
The glycated hemoglobin level
was reduced by 46% in drug group
versus placebo group; ratio of
proinsulin to insulin was markedly
lower in the anakinra group
Reduction of pain visual analog
scale, improvement in disease
activity assessment, reduction in
inflammation, reduction in
analgesics and NSAIDS
Frequency and severity of fever
attacks were reduced

Response/outcome

5–10 days

2 weeks to
6 months

2 weeks to
3 months

3 months

7–10 days

3 months

18 months

1 month

13 weeks

,1 week

Time to
response

None

Flu-like symptoms, diarrhea,
and myalgias

Slight neutropenia

Unknown

None

Injection site reactions
and initial transient mild
headaches

Injection site reaction

Injection site reaction

Pain at injection site 90%,
1 kala-azar, 4 viral infections,
2 transient headaches
Injection site reactions,
nausea, URI, UTI

Adverse effects

Abbreviations: AS, ankylosing spondylitis; CRP, C-reactive protein; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; URI, upper respiratory infection; UTI, urinary tract infection; SAPHO, synovitis,
acne, pustulosis, hyperostosis, osteitis.

Familial
Mediterranean
fever

Osteoarthritis of
the hand

Bacconnier
et al48

Stankovic
Stojanovic
et al49

Behçet’s disease

Botsios
et al47

Tan et al46

Disease state

Reference

Table 3 Diseases showing positive effects of treatment with anakinra
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as hearing loss, papilledema, chronic meningitis, or mental
retardation. These observations illustrate the need for prompt
recognition and treatment of all CAPS phenotypes, including NOMID.
As demonstrated in the many studies of diseases treated
by anakinra, the upstream mechanism or gene defect in a
disease does not have as much influence as the downstream
effects, including IL-1β overproduction. In NOMID syndrome, mutations in CIAS1 are found in about 50% of
patients, and appear to be only one of the underlying genetic
defects in this group of diseases. Recent studies suggest that
treatment of patients with normal CIAS1 genetic sequencing
may be successful by correction of the downstream effects
(IL-1β overproduction) regardless of the upstream mechanism (CIAS1 defect). This imbalance of IL-1β production
can be alleviated by administration of anakinra. Anakinra
has been shown to achieve rapid and sustained clinical
remission for the majority of CAPS patients, including
NOMID syndrome, and many other disease states.
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